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Summary
 Background Breast cancer patients’ long-term survival rate depends on many factors, such as 
the biological features of the tumour, stage of disease and mode of treatment. In 
most cases, in management of breast cancer combination therapy is used, accord-
ing to indications. Qualiﬁ cation for adjuvant therapy is based on the assessment 
of several factors of established prognostic and predictive values. As a standard the 
patient’s age, primary tumour size, axillary lymph node involvement, cancer histo-
logical type, its malignancy grade and steroid receptor expression are considered
 Aim Analysis of status of selected immunohistochemical markers in a set of consecu-
tive patients undergoing surgery for breast cancer.
 Materials/Methods Samples from 623 patients were examined. Colour reaction was used for oestro-
gen (ER) and progesterone (PgR) receptors, P53 protein, cathepsin D and c-
erbB-2. Overexpression of HER-2 protein was examined in 150 patients.
 Results The presence of oestrogen receptors in cell nuclei was detected in 431 (69.2%) 
patients, of progesterone receptors in 504 (80.2%), and ER+, PgR+ phenotype in 
382 (61%) patients. Cathepsin D expression was observed in 438 (70.3%) subjects. 
In 176 (27.3%) patients P53 protein accumulation was observed. Oncoprotein c-
erbB-2 overexpression was observed in 99 (15.9%) and overexpression of HER-2 
receptor in 29 (19.8%) patients.
 Conclusions Nowadays oestrogen receptors are detected more frequently than in patients treated 
in the years 1980–1986. Detection rates of cathepsin D and P53 protein expression 
remain at comparable levels. The difference observed in detection rate of c-erbB-
2 expression requires further analysis. Assessment of the correlation between ex-
pression of studied immunohistochemical markers and survival rate is necessary.
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BACKGROUND
Breast cancer patients’ long-term survival rate de-
pends on many factors, such as the biological fea-
tures of the tumour, stage of disease and mode of 
treatment. In most cases, in management of breast 
cancer combination therapy is used, according to 
indications. Qualiﬁ cation for adjuvant therapy is 
based on the assessment of several factors of estab-
lished prognostic and predictive values. As a stand-
ard the patient’s age, primary tumour size, axillary 
lymph node involvement, cancer histological type, 
its malignancy grade and steroid receptor expres-
sion are considered [1]. According to the guide-
lines of the American Joint Committee on Cancer 
(AJCC), expression of HER-2 receptor was added 
to the group of prognostic factors in 2002 [2]. In 
spite of many years of studies on the usefulness of 
marker expression determination, the Nottingham 
Index parameters (based on tumour size – T, lymph 
node stage – T, and histological tumour grade – 
G) remain a reliable prognostic tool. Markers that 
are intensively studied among others include: c-
myc, pS2, MDR; suppressor genes and their prod-
ucts (p53, Rb1, BRCA-1 i BRCA-2); receptors for 
growth factor: EGFR – epithelial growth factor, c-
erbB-2, IGF-IR – insulin-like growth factor; markers 
of high metastasis risk, e.g. cathepsin D, plasmino-
gen activator, nm-23; markers of tumour prolifer-
ative activity: MI – mitotic index, TLI – thymidine 
index, SPF – S-phase fraction, proliferation cell 
nuclear antigen PCNA antibody, Ki-67 antibody; 
DNA ploidy; tumour angiogenesis markers; heat 
shock proteins and others (CEA – carcinoembry-
onic antigen, vimentin, blood group antigens and 
lectins – PNA, HPL [3,4].
Detection of selected immunohistochemical mark-
ers combined with assessment of some pathoclin-
ical features in patients treated with surgery for 
glandular breast cancer in the years 1980–1986 
allowed us to determine the group of factors with 
a statistically signiﬁ cant inﬂ uence on overall sur-
vival rate as well as to construct a prognostic in-
dex for a group of patients with no metastases to 
axillary lymph nodes. Routine assessment of the 
following markers was recommended: oestrogen 
receptor expression ER, P53 protein accumula-
tion, cathepsin expression CD and c-erbB-2 pro-
tein expression [5].
Our later studies on invasive lobular cancer al-
lowed us to formulate the prognostic index for 
this cancer type, in which – in spite of assessment 
of numerous immunohistochemical markers – the 
only independent prognostic factors were: size 
of the tumour, state of lymph nodes and expres-
sion of receptors for progesterone [6].
AIM
The aim of the present study was to analyse as-
sessments of selected markers performed in a 
set of consecutive patients undergoing surgery 
for breast cancer in the years 1998–2003, and to 
compare their results with those obtained from 
studies from the 1980–1986 period. In the future 
(after the time necessary for 5-year survival assess-
ment) an analysis of the relation between expres-
sion of selected clinical, morphological and im-
munohistochemical factors and overall survival 
rate will be performed. Thus an attempt to de-
ﬁ ne a universal prognostic index, independent 
of histological cancer type, will be made.
MATERIALS AND METHODS
Immunohistochemical assays were performed 
in the Immunohistochemical Laboratory of 
the Department of Tumour Pathology in the 
Department of Oncology, University of Medical 
Sciences, Poznań. Selected markers’ expression 
(ER, PgR, P53 protein, CD, c-erbB-2 and HER-
2) was assessed in parafﬁ n wax embedded breast 
tissue from 623 patients undergoing surgery 
for breast cancer in the Oncological Surgery 
Department of the Oncology Department in the 
years 1998–2003 (group A). Receptors for oes-
trogens and progesterone, as well as P53 pro-
tein, were detected in the nuclei of cancer cells 
using the EnVision+™/HRP (Mouse) meth-
od, cathepsin D in cytoplasm using complex 
EnVision+™/HRP (Rabbit), and c-erbB-2 mem-
brane staining was performed according to the 
ABC technique. Moreover, for the past two years 
HER-2 protein overexpression has been routinely 
assessed using the DAKO Hercept Test, with pos-
itive results in 150 patients. Assessments of con-
trol reactions and colour reactions have been car-
ried out according to uniﬁ ed criteria accepted 
in the Immunohistochemical Laboratory of the 
Department of Tumour Pathology in the Oncology 
Department, and for the Hercept Test observing 
the manufacturer’s guidelines. Examples of col-
our reactions are shown in Figures 1 and 2.
The results were compared with those obtained 
from a group of 617 patients treated in the years 
1980–1986, from which immunohistochemical 
assays were performed in the years 1996–1997 
(group B). ER and P53 expression was deter-
mined using the ABC method (Autoclave), CD 
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with modiﬁ ed PAP method, and c-erbB-2 with 
three-step ABC method.
RESULTS
Presence of receptors for oestrogens ER and pro-
gesterone PgR, as well as P53 and cathepsin ex-
pression, was examined in all 623 patients, and 
HER-2 overexpression in 150 patients treated in 
the years 1998–2003. In patients presenting for di-
agnostic work-up only markers considered useful 
for prognosis based on our own results were test-
ed, as well as receptors for progesterone and HER-
2 – which have not been examined previously.
The presence of oestrogen receptors in cell nuclei 
was detected in 431 (69.2%) patients, of progester-
one receptors in 504 (80.2%), and ER+, PgR+ phe-
notype in 382 (61%) patients. In 176 (27.3%) pa-
tients P53 protein accumulation was observed.
In our group overexpression of HER-2 receptor 
was detected in 29 (19.8%) patients, and among 
those a high degree of overexpression (+3) was 
determined in 19 (12.7%) and a moderate de-
gree (+2) requiring conﬁ rmation with FISH test 
in 10 (6.7%).
Oncoprotein c-erbB-2 overexpression was ob-
served in 99 (15.9%).
In 176 (27.3%) patients P53 protein accumula-
tion was observed – a result similar to those found 
in the literature.
Cathepsin D expression in our group was ob-
served in 438 (70.3%) subjects.
Results are presented in Table 1.
In Table 2 status of HER-2 expression in a group 
of 150 patients treated in the years 1998-2003 is 
shown.
In Table 3 results of tests for selected markers in 
parafﬁ n wax embedded breast tissue from 617 
breast cancer patients from the years 1980–1986 
(group B) are presented.
DISCUSSION
The usefulness of oestrogen and progesterone 
receptor expression evaluation is unquestiona-
ble and as such it remains a standard procedure 
in breast cancer management. Presence of these 
Group A n=623 (100%) pN0 n=354 (56.8%) pN1 n=269 (43.2%)
ER+  431 (69.2%)  226 (52.4%)  205 (47.6%)
PgR+  504 (80.2%)  246 (48.8%)  258 (51.2%)
ER+ i PgR+  382 (61%)  189 (49.5%)  193 (50.5%)
katepsyna D+  438 (70.3%)  209 (47.7%)  229 (52.3%)
P53+  176 (27.3%)  93 (52.8%)  83 (47.2%)
c-erbB-2  99 (15.9%)  42 (42.4%)  57 (57.8%)
Table 1. Expression of selected immunohistochemical markers in a group of 623 patients treated surgically in the years 1998–2003 (group A).
Figure 1. Reakcja barwna nadekspresji białka HER2. Figure 2. Reakcja barwna obecności receptorów progesteronu.
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receptors is a classical favourable prognostic and 
predictive factor. In approximately 60% of pa-
tients both receptor types are found, in 20% one 
type, and in the remaining 20% no receptors are 
present [7–10].
ER expression frequency of nearly 70% and PgR 
expression of 80% of our group A patients, as 
well as phenotype ER+ PgR+ in 61% are similar 
to the literature data [4,5,9,12]. For oestrogen 
receptors the results are signiﬁ cantly higher in 
group A than in B (69.2% vs 50.2%). One possi-
ble explanation of this observation is a difference 
in sample conservation technique in compared 
time periods. Another may be a possible loss of 
a certain part of archived material. Even higher 
ER+ (72.6%) and PgR+ (82.4%) frequency were 
observed in our studies on lobular cancer, which 
is a known feature of this histological type of tu-
mour [6]. HER-2 overexpression in 19.8% also 
matches the results reported in the literature.
Overexpression of HER-2 protein (acting as a mem-
brane receptor stimulating cellular growth) cor-
relates with lymph node metastases, higher histo-
logical malignancy, higher mitotic activity, lack of 
oestrogen receptors (meaning worse response to 
hormonal therapy), early disease relapse and with 
overall shorter survival period. At the same time, 
detecting HER-2 expression enables the selection 
of patients who may beneﬁ t from monoclonal 
antibody therapy [9,10,12–14] (Trastuzumab), 
which block the extracellular part of the receptor. 
Remission rate in therapy with trastuzumab is esti-
mated to reach nearly 40%. Qualiﬁ cation for adju-
vant therapy of HER-2–2+ patients may be problem-
atic, since in 75% of examined subjects ﬂ uorescent 
in situ hybridization does not detect gene ampli-
ﬁ cation and in those patients no clinical beneﬁ ts 
from trastuzumab therapy are observed [15].
For the samples from 1999–2003 there were no 
signiﬁ cant differences observed between the 
positive reaction for c-erbB-2 receptor overex-
pression rate using three-step ABC technique 
and Herceptest (15.9% vs 12.7% HER-2–3+). In 
archival material c-erbB-2 overexpression was 
present in nearly 35% of the patients. This dis-
crepancy may result from different criteria of 
colour reaction evaluation, since in its ﬁ nal in-
terpretation the 1+, 2+, 3+ groups were not dif-
ferentiated. In fact, in no more than 16% of the 
c-erbB-2+ group were the reactions evaluated as 
2+ and 3+. Another explanation may be hetero-
geneity of the compared groups. In recent years 
earlier stages of the cancer are more often diag-
nosed, and 56.8% of the subjects were metasta-
sis-free (in this group cerbB-2 expression is sig-
niﬁ cantly lower: 42% vs 58%). In comparison, 
in the group of previously examined patients ap-
proximately 48% had pN0 status.
The suppressor gene product P53 protein is re-
sponsible for stopping replication and for activat-
ing DNA repair in the case of DNA damage de-
tection; it may also initiate apoptosis. P53 gene 
mutation is connected with later disease stages 
and thus with a shorter disease-free period and 
shorter overall survival time [1,4,9,15–19].
The higher number of P53+ patients in our lymph 
node metastasis-free subgroup is unclear. This 
HER-2 n=150 (100%) pN0 n=72 (48%) pN1 n=78 (52%)
HER-2 (+3)  19 (12.7%)  6 (4%)  13 (8.7%)
HER-2 (+2)  10 (6.7%)  4 (2.7%)  6 (4%)
Table 2. HER-2 expression in a group of 150 patients.
Group B n=617 (100%) pN0 n=302 (48.9%) pN1 n=315 (51.1%)
ER+  310 (50.2%)  158 (50.9%)  152 (49.1%)
cathepsin D +  413 (66.9%)  194 (47%)  219 (53%)
P53 +  132 (21.4%)  63 (47.7%)  69 (52.3%)
c-erbB-2 +  217 (35.2%)  87 (40.1%)  130 (59.9%)
Table 3. Expression of selected immunohistochemical markers in a group of 617 patients treated surgically in the years 1980–1986 (group B).
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observation requires an analysis of the correla-
tion with survival period and disease-free peri-
od. Especially interesting may be the evaluation 
of survival time of patients with accumulation of 
unfavourable prognostic factors: HER-2 receptor 
overexpression and P53 protein accumulation. 
According to Yamashita et al., a combination of 
excess of these two proteins may be a remarka-
bly bad prognostic factor [16].
Excessive cathepsin D (CD) expression in breast 
cancer results from induction by oestrogens. CD 
overexpression correlates with shorter disease-
free and survival periods [3,4].
In both our groups CD overexpression was ob-
served in nearly 70% of patients, and in both 
groups less frequently in pN0 than in pN1 pa-
tients (47.7% vs. 53%). So far, observations in-
dicate that in a group of patients without node 
metastases, cathepsin overexpression has an 
independent, signiﬁ cant negative inﬂ uence 
on overall survival period [5]. No CD over-
expression inﬂ uence on survival rate in lobu-
lar cancer was observed [6]. Determination of 
the clinical signiﬁ cance of present results re-
quires further studies. Correlating present re-
sults with survival rate of glandular breast can-
cer patients will enable an attempt to deﬁ ne a 
universal prognostic index using immunohis-
tochemical markers, independent of histolog-
ical cancer type.
CONCLUSIONS
1. Nowadays oestrogen receptors are detected 
more frequently than in patients treated in the 
years 1980–1986.
2. Detection rates of cathepsin D and P53 protein 
expression remain at comparable levels.
3. The difference observed in detection rate of c-
erbB-2 expression requires further analysis.
4. Assessment of the correlation between the ex-
pression of studied immunohistochemical mark-
ers and survival rate is necessary.
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